Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03943147 · ClinicalTrials.gov registry record · Phase 2
An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT03943147 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 16 participants.
The verdict
NCT03943147, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of BMS-986165 compared with placebo with regard to measures of kidney function in participants with lupus nephritis (LN).
Interventions
- DRUG Placebo
- DRUG Mycophenolate Mofetil
- DRUG BMS-986165
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2021-09-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03943147
The ClinicalTrials.gov registry entry for NCT03943147 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03943147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03943147 about?
NCT03943147 is a clinical study titled "An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis". The purpose of this study is to evaluate the safety and effectiveness of BMS-986165 compared with placebo with regard to measures of kidney function in participants with lupus nephritis (LN).
What is the current status of trial NCT03943147?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2019-07-15. Estimated completion is 2021-09-17.
What interventions are being tested in trial NCT03943147?
The interventions under investigation include: Placebo (DRUG), Mycophenolate Mofetil (DRUG), BMS-986165 (DRUG).
Who is sponsoring clinical trial NCT03943147?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.